CP and COVID-19: In the announcement of EUA, the FDA warned about the lack of prospective RCT for the use of CP in COVID-19 patients and stated that data suggest that the use of COVID-19 CP with high antibody titer may be effective in reducing mortality in hospitalized patients with COVID-19 [100]; however, studies evaluating the efficacy of CP in COVID-19 patients have been inconclusive.